發(fā)布時(shí)間：2018-02-17 04:45

  本文關(guān)鍵詞： 阿托伐他汀鈣片 非創(chuàng)傷性硬膜下血腫 安全性　出處：《中國(guó)臨床藥理學(xué)雜志》2017年18期 　論文類型：期刊論文

【摘要】：目的觀察阿托伐他汀鈣片治療非創(chuàng)傷性硬膜下血腫的臨床療效及安全性。方法將52例非創(chuàng)傷性硬膜下血腫患者隨機(jī)分為對(duì)照組26例和試驗(yàn)組26例。對(duì)照組予以鉆孔引流術(shù)治療,封閉骨孔并進(jìn)行閉式引流2~3 d;試驗(yàn)組在對(duì)照組治療的基礎(chǔ)上,予以阿托伐他汀鈣片20 mg,qd,口服,連續(xù)用藥28 d。比較2組患者的臨床療效、血清中超氧化物歧化酶(SOD)、丙二醛(MDA)水平、復(fù)發(fā)率,以及藥物不良反應(yīng)的發(fā)生情況。結(jié)果治療后,試驗(yàn)組和對(duì)照組的總有效率分別為84.62%(22/26例)和57.69%(15/26例),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,對(duì)照組和試驗(yàn)組的SOD分別為(115.29±13.34)和(128.39±14.29)U·m L~(-1),MDA分別為(19.83±2.43)和(15.40±1.67)nmol·m L~(-1),復(fù)發(fā)率分別為26.92%(7/26例)和0(0/26例),差異均有統(tǒng)計(jì)學(xué)意義(均P0.05)。試驗(yàn)組發(fā)生的藥物不良反應(yīng)有血腫量增加和感染,對(duì)照組發(fā)生的藥物不良反應(yīng)有顱內(nèi)氣腫、血腫量增加、感染、肝功能異常、腦損傷,試驗(yàn)組和對(duì)照組的藥物不良反應(yīng)發(fā)生率分別為7.69%和34.62%,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論阿托伐他汀鈣片治療非創(chuàng)傷性硬膜下血腫的臨床療效顯著,且藥物不良反應(yīng)發(fā)生率和復(fù)發(fā)率均較低。
[Abstract]:Objective to observe the clinical efficacy and safety of Atto vastatin calcium tablets in the treatment of non-traumatic subdural hematoma. Methods 52 patients with non-traumatic subdural hematoma were randomly divided into control group (n = 26) and experimental group (n = 26). On the basis of treatment in the control group, the experimental group was given the calcium tablet of Atto vastatin 20 mg / g QD orally for 28 days. The clinical efficacy, serum levels of superoxide dismutase (SOD) and malondialdehyde (MDA) were compared between the two groups. Results after treatment, the total effective rates of the treatment group and the control group were 84.62 / 22 / 26 and 57.6969 / 15 / 26, respectively. The difference was statistically significant (P 0.05). The SOD of the control group and the trial group were 115.29 鹵13.34 and 128.39 鹵14.29 U 路mL ~ (-1), respectively (19.83 鹵2.43) and 15.40 鹵1.67 nmol 路mL ~ (-1), respectively. The recurrence rate was 26.92i / 726 cases, and there were significant differences between the two groups. Adverse drug reactions in the control group included intracranial emphysema, increased hematoma, infection, abnormal liver function, brain injury, The incidence of adverse drug reactions in the trial group and the control group were 7.69% and 34.62, respectively. The difference was statistically significant (P 0.05). Conclusion the clinical efficacy of Atto vastatin calcium tablets in the treatment of non-traumatic subdural hematoma is significant. The incidence and recurrence rate of adverse drug reactions were lower.
【作者單位】： 遵義醫(yī)學(xué)院第三附屬醫(yī)院神經(jīng)外科;
【基金】：貴州省科技計(jì)劃基金資助項(xiàng)目[SY(2012)3118]
【分類號(hào)】：R651.1
，

本文編號(hào)：1517247